Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 177Lu-DOTA-TATE with kidney dosimetry in disseminated neuroendocrine tumors
2011-000240-16Phase 2Active
- Sponsor
- Skåne University Hospital
- Start
- Apr 2011
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in apudoma (NET), sponsored by Skåne University Hospital. Primary endpoints: Efficacy of 177Lu-DOTA-TATE based on kidney dosimetry and Safety of 177Lu-DOTA-TATE with kidney dosimetry. Started Apr 2011; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2011-000240-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000240-16.